Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2001-08-17
2002-09-24
Kunz, Gary L. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C530S350000
Reexamination Certificate
active
06455687
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to the glycoprotein lactoferrin, its production, purification, and uses.
BACKGROUND OF THE INVENTION
Lactoferrin plays an important role in iron transport and utilization in humans. A glycoprotein containing about 6% sugar and having a total molecular weight of about 80,000 daltons, human lactoferrin is capable of binding two ferric ions with high affinity. Although lactoferrin binds iron tightly, the binding is reversible so that the metal is available upon demand to cells with a need for this essential element. The metal is captured by the side chains of specific amino acids: two tyrosines, one histidine and one aspartate which in combination form a cleft in the surface of the protein. That portion of the protein which contains the aforesaid four amino acids and forms the cleft is termed the “iron-binding domain.” Each natural lactoferrin molecule has two iron-binding domains.
Human milk is high in lactoferrin content. The high degree of iron absorption from human milk is manifested in a low incidence of iron deficiency anemia among breast fed infants compared to infants fed with cow's milk. Accordingly, lactoferrin is a key protein for healthy development of infants. Lactoferrin also plays an important role in cell-mediated host immunity. It is present in high concentrations in all bodily secretions, such as tears, sweat, and ciliated respiratory mucous. Because it sequesters iron, lactoferrin can neutralize pathogenic microorganisms by preventing them from obtaining necessary iron at the site of entry, thereby preventing the spread of infection.
Although iron is an essential material in humans, excess iron in the body can induce pathological conditions as well. Chronic iron overload, known as hemosiderosis, is characterized by a greater than normal local or generalized deposition of iron within certain body tissues. Lactoferrin helps to manage the balance of free iron in the body to prevent occurrence of such pathological states in healthy individuals.
The severely limited amount of human milk, the major source of human lactoferrin, restricts lactoferrin production. Furthermore, production of lactoferrin from human milk presents a risk factor of infectious contamination. That is, it could carry with it a potentially lethal contaminant, such as the human immunodeficiency virus (HIV) or another undesirable agent.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides for the cloning and expression of human lactoferrin using recombinant DNA techniques. The lactoferrin of the present invention is free of naturally occurring contaminants, e.g., proteins and viruses, that would be detrimental to the recipient.
In one embodiment of the present invention there is provided a gene comprising a DNA molecule encoding human lactoferrin protein. More particularly, the DNA molecule comprises the nucleotide sequence (Seq. ID No. 1) and the protein comprises the amino acid sequence (Seq. ID No. 2) as substantially depicted in FIG.
3
. An expression system is provided for expressing the gene encoding the protein. Preferably, the expression system is a plasmid. Also described herein, is a host cell line transformed with the gene of the present invention, i.e., the gene encoding human lactoferrin. Preferably the host cell organism is a eukaryotic cell.
In another embodiment of the invention, there is provided a method of producing human lactoferrin comprising the steps of (a) isolating a gene encoding human lactoferrin; (b) transforming a host cell with the gene; (c) culturing the transformed cells which express the gene product; and (d) collecting lactoferrin from the cells.
In a further embodiment of the invention there is described a chromatography method for purifying lactoferrin protein, and other proteins, comprising the steps of (a) contacting a substance with a first adsorbent to obtain adsorbed and non-absorbed fractions; (b) eluting the adsorbed fraction with an eluant; and (c) contacting the adsorbed fraction with a second adsorbent, wherein the improvement comprises equilibrating the second adsorbent with the eluant followed by contacting the eluate containing the adsorbed fraction with the second adsorbent.
In still a further embodiment of the invention there is provided a method for inhibiting microbial growth in a mammal comprising topically or systemically applying to a subject a therapeutically effective amount of lactoferrin having less than about 25% metal loading; a method for inhibiting iron deficiency in a mammal comprising orally administering a therapeutically effective amount of lactoferrin having at least about 35% iron loading; a nutritional supplement comprising an iron-loaded human lactoferrin having at least about 35% metal loading and a nutritionally acceptable carrier or adjuvant; a topical antiseptic comprising a therapeutically effective amount of lactoferrin having less than about 25% metal loading and a pharmaceutically acceptable carrier or diluent; and a method for inhibiting food spoilage comprising adding to the food an effective amount of lactoferrin having less than about 25% metal loading.
REFERENCES:
patent: 3234199 (1966-02-01), Reid
patent: 3969337 (1976-07-01), Laurer et al.
patent: 4436658 (1984-03-01), Peyrouset et al.
patent: 4668771 (1987-05-01), Kawskami et al.
patent: 4732683 (1988-03-01), Georgidas et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571697 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: WO 90/13642 (1990-11-01), None
“Human Lactoferrin: Amino acid sequence and structural comparision with other transferrins”, Metz-Boutigue et al., Eur. J. Biochem 145, 659-676 (1984).
Maniatis,Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Press, 1989, Chapter 14.
Davis et al.,Basic Methods on Molecular Biology, Elseiver Science Publishing Co., (1986).
Rado et al., “Isolation of Lactoferrin cDNA from a Human Myeloid Library and Expression of mRNA During Normal and Leukemic Myelopoiesis”,Blood, 70:4, 989-993, (Oct., 1987).
Tschopp,Nucleic Acid Research, vol. 15, p3859-3876, (1987).
Gellisen, “High-Level Expression of Foreign Genes in Hansenula Ploymorpha”,Biotech Adv., vol. 10, pp179-189, 1992.
Gruenwald,Baculovirus Expression Vector System: Procedures&Methods Manual, Second Edition, 1993, by Pharmagen.
Rothstein, “One-Step Gene Disruption in Yeast”,Methods in Enzymology, 101, 202-210, 1983.
Tschopp et al., “High-Level Secretion of Glycosylated Invertase in the Methylotrophic Yeast,Pichia Pastoris”,Bio/Technology, 5, 1305-1308, 1987.
Powell etal.,Nucleic Acid Research, 18, 4013, 1990.
Bezwoda et al., “Isolation of Characterisation of Lactoferrin Searated from Human whey by Adsorption Chromatography Using Cibacron Blue F3G-A Linked...”,Clin. Chem. Acta., 157, 89-94, 1986.
Chemical Abstracts Service(CAS) No. 12236-82-7.
Bohme et al., “Affinity Chromatography of Phosphofructokinase Using Cibacron Blue F3G-A”,J. Chromatography, 69, 209-214, 1972.
Sulkowski,Frontiers in Bioprocessing, Sidkar et al., Ed., 343-353, 1990.
Janson et al.,Protein Purification Principle High Resolution Methods and Applications, VSH Publishers, New York, 1989.
Gubler et al.,Gen, 40, 1-8, 1983.
Sreekrishna et al., “High-Level Expression, Purification and Characterization of Recombinant Human Tumor Necrosis Factor Synthesized...”,Biochemistry, 28, 4117-4125, 1989.
Rothstein,Methods in Enzymology, 101, 202-210, 1983.
Creeg et al.,Mol. Cell. Biol., 5, 3376-3385, 1985.
Hageneson et al.,Enzyme Microb. Technol., 11, 650-656, 1989.
Porath et al.,Enzyme Microb. Technol., 11, 19-45, 1976.
Axen et al.,Nature, 214, 1302-1304, 1967.
Sanger,Proc. Nat. Acad. Sci. USA, 74, 5463-5467, 1977.
Lacemmli, U.K., (1970),Nature, 227, 680-685.
Crichton et al., “Iron Transport and Storage”,Eur. J. Biochem., vol. 164, 485-506, 1987.
Bezwoda et al., “Lactoferrin from Human Breast Milk and from Neutrophil Granulocytes: Comparative Studies of Isolation, Quantitation”,Biomedical Chromatography, vol. 3, No. 3, 121-126, 1989.
Sulkowski, “Controlled Pore Glass Chro
Doyle Darrell J.
Gollnick Paul D.
Kruzel Marian L.
Kurecki Tomasz
FerraDynamics, Inc
Gucker Stephen
Myers Kurt S.
LandOfFree
Human lactoferrin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human lactoferrin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human lactoferrin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2895067